Wall Street Tries Out Lots of Shiny New Objects
The financial industry offers a dizzying array of products -- more than 12,000 exchange-traded funds, exchange-traded notes, and the like. But are they all really necessary? Barry Ritholtz has his doubts.
Maybe Pharmaceutical Reps Aren't Bribing Doctors
It sure looks unseemly when drug companies host lavish feasts for physicians, but what if they offer sales pitches over free hoagies? There's new evidence that even cheap meals influence prescriber behaviors, but Megan McArdle is skeptical doctors making $400,000 will sell out for a sandwich.
Volkswagen Is in Too Much of a Hurry to Move On
The German carmaker has ambitious plans for the future, but it still needs to make a clean break with its past. Leonid Bershidsky lays out what it'll take to put the diesel emissions scandal behind it.
The Fed May Not See It, But There's Reason for Optimism
More Problems for Donald Trump
He's falling behind in the polls, his spending is under scrutiny, his donors are getting frustrated -- and that's just the start of the bad news for the presumptive presidential nominee. Paula Dwyer parses a new report from Moody's predicting the U.S. would lose 3.4 million jobs and almost $10 billion in tax revenue under Trump, while Margaret Carlson explains why his response to the Orlando massacre put his already-struggling party in a bind.
- Potential pitfalls of negative rates (Fidelity)
- The psychology of buying and selling a house (Wall Street Journal
- A dozen things I've learned from Elon Musk about business and investing (25iq)
(Read Barry Ritholtz's full daily news roundup.)
- Tesla's SolarCity eclipse
- The magic number for software companies
- London's property market has more to fear than Brexit
(Read more from BV's sister site for fast business commentary.)
Get Share the View every morning in your inbox. Click here to subscribe.
This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.